...
首页> 外文期刊>Bone marrow transplantation >Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts
【24h】

Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts

机译:具有部分T细胞耗尽的PBSC移植物移植的儿童的有利免疫恢复和GVHD的低速率

获取原文
获取原文并翻译 | 示例
           

摘要

Transplantation of peripheral blood stem cells (PBSC) from matched unrelated donors (MUD) is still associated with a significant risk for graft vs. host disease (GvHD), especially in pediatric patients receiving grafts from adult donors containing high amounts of T cells. Here, we present long-term follow-up results on 25 pediatric patients, (acute leukemia n = 15, NHL n = 3, CML n = 3, MDS n = 5), transplanted with CD34 or CD133 positively selected PBSC from MUDs supplemented with an add-back of 1 x 10(7)*/kg body weight (kgBW) unselected T cells resulting in a median T-cell depletion (TCD) of 1.97 log. A total of 24*/25 (96%) patients had primary engraftment. Early T-cell recovery was significantly improved compared to patients receiving CD34-selected grafts without T-cell add-back and similar to patients receiving unmanipulated bone marrow. GvHD incidence was low with 8*/4% aGvHD grade II*/III, no grade IV and 13% limited cGvHD. In total, 16*/25 (64%) patients are alive after a median follow-up of 10 years. Five-year event-free survival (EFS) was 68%, relapse probability 24% and transplantation-related mortality (TRM) 12%. Thus, in PBSC allotransplants from MUD, partial TCD with serotherapy and CSA*/MTX prophylaxis, can effectively reduce GvHD without hampering engraftment and immune reconstitution.
机译:外周血干细胞(PBSC)从匹配的不相关供体(泥浆)的移植仍然与移植物与宿主疾病(GVHD)的显着风险相关,特别是在接受来自含有大量T细胞的成人供体移植物的小儿患者中。在这里,我们呈现25名儿科患者的长期随访结果(急性白血病N = 15,NHL N = 3,CML N = 3,MDS N = 5),用CD34或CD133移植,阳性选择PBSC从补充的泥浆中加入背面为1×10(7)* / kg体重(kgbw)未选择的t细胞,导致1.97 log的中值t细胞耗尽(tcd)。共24 * / 25(96%)患者有初级植入。与接受CD34-选自接枝的患者的患者相比,早期T细胞回收率显着改善,没有T细胞加回来,类似于接受非法骨髓的患者。 GVHD发病率低,8〜4%AGVHD级* / III,无级和13%限量CGVHD。总共有16 * / 25(64%)患者在10年后的中位随访后活着。五年的无事项存活率(EFS)为68%,复发概率24%和移植相关的死亡率(TRM)12%。因此,在PBSC来自泥浆的分征物植物中,部分TCD与血管疗法和CSA * / MTX预防,可以有效地减少GVHD而不会妨碍植入和免疫重建。

著录项

  • 来源
    《Bone marrow transplantation》 |2019年第1期|共10页
  • 作者单位

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Univ Childrens Hosp Dept Hematol Oncol &

    Stem Cell Transplantat D-97080 Wurzburg Germany;

    Univ Childrens Hosp Dept Hematol Oncol D-69120 Heidelberg Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Dr von Haunersches Kinderspital Dept Hematol Oncol &

    Stem Cell Transplantat D-80337 Munich;

    Univ Childrens Hosp Div Stem Cell Transplantat &

    Immunol D-60590 Frankfurt Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Univ Childrens Hosp Dept Hematol Oncol &

    Stem Cell Transplantat D-97080 Wurzburg Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

    Univ Childrens Hosp Dept Gen Pediat Hematol Oncol D-72076 Tubingen Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号